Market watchers can wag their tongues all they like, says Bayer CEO Werner Wenning (photo [1]). The company isn't vulnerable to a takeover, he told a German newspaper, because its market cap of €42 billion is just too much for a suitor to swallow. Wenning acknowledged that "you can't rule out anything, especially not in the current environment," but allowing for a slim possibility isn't the same thing as admitting a fair chance.

You'll recall that last week, rumors [2] of a Pfizer takeover boosted Bayer shares, in spite of the fact that Pfizer has been pooh-poohing talk [3] of doing any big buyout deals. Wenning's reponse didn't stop traders from bidding up Bayer stock yet again, this time to a seven-month high.

Meanwhile, Bayer has been working on a deal of its own: It has agreed to acquire the German drug developer Direvo Biotech for $298 million [4]. A protein engineering expert, Direvo will help beef up Bayer's capabilities in biologic drugs [5].

- read the Pharmalot item [6]
- check out the AP story [7]
- here's the release [8] on the Direvo buyout

Related Articles:
Bayer up on Pfizer buyout talk [9]
Bayer plans to beef up biotech pipeline [10]
Direvo pockets $17M in investment round [11]